Title

Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion

Authors

Authors

E. Gomes-Giacoia; M. Miyake; S. Goodison; A. Sriharan; G. Zhang; L. J. You; J. O. Egan; P. R. Rhode; A. S. Parker; K. X. Chai; H. C. Wong;C. J. Rosser

Comments

Authors: contact us about adding a copy of your work at STARS@ucf.edu

Abbreviated Journal Title

PLoS One

Keywords

BACILLUS-CALMETTE-GUERIN; UROTHELIAL CARCINOMA; GENE-THERAPY; N-BUTYL-N-(4-HYDROXYBUTYL) NITROSAMINE; MITOMYCIN-C; STAGE-TA; IMMUNOTHERAPY; INTERLEUKIN-15; EXPRESSION; IL-15; Multidisciplinary Sciences

Abstract

Intravesical Bacillus Calmette-Guerin (BCG) has been shown to induce a specific immunologic response (i.e., activation of IL-2 and effector T-cells), while preclinical studies using ALT-803 (mutated IL-15 analogue combined with IL-15R alpha-Fc fusion) have shown promising results by prolonging the agent's half-life and stimulating CD8+ T-cells. Based on these results, we hypothesized that the intravesical administration of ALT-803 along with BCG will generate an immunologic response leading to significant bladder tumor burden reduction. Using a well-established carcinogen induced rat non-muscle invasive bladder cancer (NMIBC) model, we studied the effects of intravesical ALT-803 with and without BCG. Rat tissues were evaluated to document treatment response. Intravesical ALT-803 was safe and well tolerated alone and in combination with BCG. As a single treatment agent, ALT-803 reduced tumor burden by 35% compared to control whereas BCG alone only reduced tumor burden by 15%. However, the combination of ALT-803 plus BCG reduced tumor burden by 46% compared to control. Immune monitoring suggested that the antitumor response was linked to the production and secretion of IL-1 alpha, IL-1 beta and RANTES, which in turn, induced the proliferation and activation of NK cells. Lastly, tumoral responses of the combinational treatment were associated with 76% reduction in angiogenesis, which is significantly higher than when assessed with either agent alone. The enhanced therapeutic index seen with this duplet provides justification for the development of this regimen for future clinical trials.

Journal Title

Plos One

Volume

9

Issue/Number

6

Publication Date

1-1-2014

Document Type

Article

Language

English

First Page

11

WOS Identifier

WOS:000338430700004

ISSN

1932-6203

Share

COinS